COMMUNIQUÉS West-GlobeNewswire

Sébastien Dallais nommé Directeur Commercial et Marketing France de Medasys

28/09/2017 - 18:35

Sa nomination effective depuis le 4 septembre dernier coïncide avec la volonté du Groupe de se positionner stratégiquement sur les nouveaux besoins des territoires de soins. Clamart, le 28 septembre 2017 - Medasys, [...]

HALF-YEAR CONSOLIDATED RESULTS: STABILITY OF NET LOSS & MAJOR PROGRESS ON R&D PROGRAMS

28/09/2017 - 18:30

2017 HALF-YEAR CONSOLIDATED RESULTS: STABILITY OF NET LOSS MAJOR PROGRESS ON R&D PROGRAMS IN HEALTH, NUTRITION AND COSMETICS · Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. · Half- [...]

NANOBIOTIX prévoit de lancer aux Etats-Unis son premier essai clinique avec NBTXR3 en combinaison avec des « immune checkpoints inhibitors »

28/09/2017 - 18:29

Nanobiotix prévoit de lancer aux Etats-Unis son premier essai clinique avec NBTXR3 en combinaison avec des « immune checkpoints inhibitors » L'étude multibras vise des sous-populations de patients atteints de cancers [...]

NANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.

28/09/2017 - 18:29

Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. Multi-arm trial targets sub-population of advanced lung, and head and neck cancer patients [...]

Summit Therapeutics plc : Exercise of Share Options

28/09/2017 - 18:15

Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 28 September 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing [...]

ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

28/09/2017 - 17:35

Press release Leuven, Belgium, 28 th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, today [...]

UPDATE ON VOLUNTARY OFFER FOR WEIFA ASA - ACCEPTANCES AT APPROXIMATELY 90.3 %

28/09/2017 - 16:00

Reference is made to the offer document dated 11 September 2017 regarding Karo Pharma AB's ("Karo Pharma") conditional voluntary offer (the "Voluntary Offer") to acquire all of the shares in Weifa ASA ("Weifa") at NOK [...]

Terveystalo Plc applies for its shares to be listed on the Official List of Nasdaq Helsinki Ltd

28/09/2017 - 14:55

TERVEYSTALO PLC STOCK EXCHANGE RELEASE September 28, 2017 at 15:55 pm EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL [...]

Auris Medical Announces Transfer to Nasdaq Capital Market

28/09/2017 - 14:30

Zug, Switzerland, September 28, 2017 - Auris Medical Holding AG (the "Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, [...]

ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference

28/09/2017 - 13:30

Presentation highlights the use of ProMIS' proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases TORONTO and CAMBRIDGE, Mass., Sept. 28, 2017 ( [...]

Allergy Therapeutics: Preliminary Results

28/09/2017 - 13:00

Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Preliminary Results 28 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy [...]

European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT's lead product

28/09/2017 - 08:30

The Paediatric Committee (PDCO) at the European Medicines Agency (EMA) has adopted a positive opinion on the Paediatric Investigation Plan (PIP) proposed by IBT for the development of IBP-9414 for the prevention of [...]

Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study

28/09/2017 - 08:00

Press Release 28 September 2017 Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study --Topline Safety and Immune Response Data Support Continued Development of Ilixadencel in Liver Cancer-- [...]

Wraptor présente sa nouvelle release Jeebop MSSanté

28/09/2017 - 07:26

Wraptor, éditeur de solutions dédiées au monde de la santé, premier éditeur à connecter un site pilote lors de l'expérimentation de l'ASIP en 2014, annonce la disponibilité de la nouvelle version de Jeebop MSSanté [...]

Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.

28/09/2017 - 07:15

Basel, Switzerland, September 28, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license agreement with Shenzhen China Resources [...]

Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets

28/09/2017 - 07:15

Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and Chemistry Technologies [...]

Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union

28/09/2017 - 07:00

Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union - First targeted biologic in the European Union to receive [...]

Sanofi et Regeneron annoncent l'approbation de Dupixent® (dupilumab) dans l'Union européenne pour le traitement de la dermatite atopique modérée à sévère de l'adulte

28/09/2017 - 07:00

Sanofi et Regeneron annoncent l'approbation de Dupixent ® (dupilumab) dans l'Union européenne pour le traitement de la dermatite atopique modérée à sévère de l'adulte - Premier médicament biologique ciblé à bénéficier d [...]

TiGenix to participate and present at key investor and business development meetings

28/09/2017 - 07:00

PRESS RELEASE TiGenix to participate and present at key investor and business development meetings Leuven (BELGIUM) - September 28, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced [...]